ANI Pharma enhances generics and CDMO business through Novitium acquisition
The transaction expands ANI’s R&D pipeline and adds nine new customers to its growing CDMO business
ANI Pharmaceuticals has completed its acquisition of New Jersey-based Novitium Pharma, a move which sees the diversified biopharma company boost its development, manufacturing and commercilisation capabilities.
Since signing the deal back in March this year, Novitium has scored 13 new drug approvals (several of which were limited competition launches), completed a successful FDA GMP inspection, and reported strong EBITDA growth.
In the next 18 months, the company plans to launch 20+ new products, including those with Competitive Generic Therapy designation.
Novitium's founders, Samy Shanmugam, Chad Gassert and Vijay Thorappadi, will drive the combined company's R&D division.
As well as expanding ANI's R&D pipeline focused on niche opportunities, the transaction also expands dosage forms to include injectables and gels.
Acquiring Novitium also adds nine new customers to ANI's CDMO business and a state-of-the-art manufacturing facility in East Windsor, New Jersey, enhancing manufacturing capabilities and CDMO opportunities.
Recently raised funds also provides ANI the flexibility to integrate Novitium into the company and fund commercialisation efforts for its Purified Cortrophin Gel for multiple indications including multiple sclerosis, rheumatoid arthritis and nephrotic syndrome.
Nikhil Lalwani, President and CEO of ANI described Novitium as a "world-class R&D engine in the generic and 505 (b)(2) sectors" with a "highly compliant" manufacturing facility.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance